Regulatory reviews for this indication are ongoing in China and Japan. Fabhalta received its first FDA approval in December 2023 for the treatment of adults with paroxysmal nocturnal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback